ARTICLE | Clinical News

Pfizer, Astellas report detailed data for Xtandi in non-metastatic CRPC

February 9, 2018 4:17 PM UTC

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (Tokyo:4503) reported detailed data from the Phase III PROSPER trial to treat non-metastatic castration-resistant prostate cancer (CRPC) showing that once-daily 160 mg oral Xtandi enzalutamide plus androgen deprivation therapy led to median metastasis-free survival (MFS), the primary endpoint, of 36.6 months vs. 14.7 months for androgen deprivation therapy alone (HR=0.29, 95% CI: 0.24, 0.35, p<0.0001). Data were presented the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

In September, the partners said Xtandi plus androgen deprivation therapy met the primary endpoint in PROSPER, but did not report specific data (see BioCentury, Sept. 15, 2017)...

BCIQ Company Profiles

Astellas Pharma Inc.

Pfizer Inc.

BCIQ Target Profiles

Androgen receptor